Glauce Lunardelli Trevisan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Glauce Lunardelli Trevisan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Evânio Vilela Silva
Oral Medicine, Department of Diagnosis and Surgery, Araraquara Dental School, São Paulo State University (UNESP), Araraquara, Brazil
1 shared publication - Fernando Chahud
University of São Paulo
1 shared publication - Heitor Albergoni Silveira
Department of Oral Diagnosis and Surgery, State University of Northern Paraná (UENP), Jacarezinho, Brazil
1 shared publication - Jorge Esquiche León
Oral Pathology, Department of Stomatology, Public Oral Health, and Forensic Dentistry, Ribeirão Preto Dental School (FORP/USP), University of São Paulo, Ribeirão Preto, Brazil
1 shared publication - Luciana Yamamoto Almeida
Craniofacial Anomalies and Regeneration Section National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health Bethesda Maryland USA
1 shared publication - Léa Assed Bezerra da Silva
Universidade de São Paulo
1 shared publication
Latest Publications
- 1 August 2020
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 92 (6) , e12950
Immunohistochemical characterization of immune cell infiltration in paediatric and adult Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia commonly affecting children with frequent somatic mutations in MAPK pathway genes including BRAFV600E and MAP2K1. Some studies suggest that LCH cells can recruit and modulate inflammatory cells, which could provide reciprocal survival signals. To characterize the immune profile of infiltrating inflammatory cells, and to clarify their participation in LCH pathogenesis, a detailed immunohistochemical analysis was performed. Fifteen (10 children, 5 adults) LCH cases were assessed through macrophage (CD68 and CD163), mature dendritic cell (mDC; CD83 and CD208), regulatory T cell (Treg; CD4, CD25 and FOXP3) and cytotoxic lymphocyte (CL; CD56, CD57, perforin and granzyme B) immunomarkers. Moreover, lymphocytic and LCH markers were also analysed. All cases were S100, CD1a, CD207 and CD4‐positive. Bcl‐2 and cyclin D1 expression was observed in 13 of 15 cases. In the immune microenvironment, M2‐polarized macrophages and Tregs were the predominant cell populations, followed by significantly (P < .005) smaller levels of mDCs and CLs. Additionally, the number of CD3 + cells was significantly higher than that of CD20 + cells. In the CD3 + cell population, there were a significantly higher number of CD4 + cells than CD8 + cells. While there were no differences when comparing the paediatric and adult populations, FOXP3 + cells were significantly higher in patients with multisystem involvement and treated with chemotherapy, than single‐site cases and those without chemotherapy. Our results suggest that M2‐polarized macrophages and Treg infiltration can promote LCH development and survival, probably through pro‐tumoral, immunosuppressive and/or cytokine‐mediated mechanisms. This work highlights the need for further exploration of immune‐targeted therapy for LCH.
- 1 August 2020
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 92 (6) , e12950
Immunohistochemical characterization of immune cell infiltration in paediatric and adult Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia commonly affecting children with frequent somatic mutations in MAPK pathway genes including BRAFV600E and MAP2K1. Some studies suggest that LCH cells can recruit and modulate inflammatory cells, which could provide reciprocal survival signals. To characterize the immune profile of infiltrating inflammatory cells, and to clarify their participation in LCH pathogenesis, a detailed immunohistochemical analysis was performed. Fifteen (10 children, 5 adults) LCH cases were assessed through macrophage (CD68 and CD163), mature dendritic cell (mDC; CD83 and CD208), regulatory T cell (Treg; CD4, CD25 and FOXP3) and cytotoxic lymphocyte (CL; CD56, CD57, perforin and granzyme B) immunomarkers. Moreover, lymphocytic and LCH markers were also analysed. All cases were S100, CD1a, CD207 and CD4‐positive. Bcl‐2 and cyclin D1 expression was observed in 13 of 15 cases. In the immune microenvironment, M2‐polarized macrophages and Tregs were the predominant cell populations, followed by significantly (P < .005) smaller levels of mDCs and CLs. Additionally, the number of CD3 + cells was significantly higher than that of CD20 + cells. In the CD3 + cell population, there were a significantly higher number of CD4 + cells than CD8 + cells. While there were no differences when comparing the paediatric and adult populations, FOXP3 + cells were significantly higher in patients with multisystem involvement and treated with chemotherapy, than single‐site cases and those without chemotherapy. Our results suggest that M2‐polarized macrophages and Treg infiltration can promote LCH development and survival, probably through pro‐tumoral, immunosuppressive and/or cytokine‐mediated mechanisms. This work highlights the need for further exploration of immune‐targeted therapy for LCH.